medical’s

Sirtex Medical’s DOORwaY90 Study Demonstrates 100% Local Tumor Control with SIR-Spheres, Setting a New Benchmark in Y-90 for HCC

The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99%WOBURN, Mass., April 13,…

1 week ago

Sirtex Medical’s SIR-Spheres Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma…

10 months ago